Pterostilbene Inhibits Lipogenic Activity similar to Resveratrol or Caffeine but Differently Modulates Lipolysis in Adipocytes
Saioa Gomez-Zorita
INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut. National de la Santé et de la Recherche Médicale and Université Paul Sabatier, Toulouse, France
Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country (UPV/EHU) and Lucio Lascaray Centre, Vitoria, Spain
CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III (ISCIII), Spain
Search for more papers by this authorChloé Belles
INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut. National de la Santé et de la Recherche Médicale and Université Paul Sabatier, Toulouse, France
DIVA expertise, Centre Pierre Potier, Toulouse, France
Search for more papers by this authorAnaïs Briot
INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut. National de la Santé et de la Recherche Médicale and Université Paul Sabatier, Toulouse, France
Search for more papers by this authorAlfredo Fernández-Quintela
Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country (UPV/EHU) and Lucio Lascaray Centre, Vitoria, Spain
CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III (ISCIII), Spain
Search for more papers by this authorMaria P. Portillo
Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country (UPV/EHU) and Lucio Lascaray Centre, Vitoria, Spain
CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III (ISCIII), Spain
Search for more papers by this authorCorresponding Author
Christian Carpéné
INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut. National de la Santé et de la Recherche Médicale and Université Paul Sabatier, Toulouse, France
Correspondence to: Christian Carpéné, Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, INSERM U1048, Bat L4, CHU Rangueil, 31432 Toulouse, France.
E-mail: [email protected]
Search for more papers by this authorSaioa Gomez-Zorita
INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut. National de la Santé et de la Recherche Médicale and Université Paul Sabatier, Toulouse, France
Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country (UPV/EHU) and Lucio Lascaray Centre, Vitoria, Spain
CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III (ISCIII), Spain
Search for more papers by this authorChloé Belles
INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut. National de la Santé et de la Recherche Médicale and Université Paul Sabatier, Toulouse, France
DIVA expertise, Centre Pierre Potier, Toulouse, France
Search for more papers by this authorAnaïs Briot
INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut. National de la Santé et de la Recherche Médicale and Université Paul Sabatier, Toulouse, France
Search for more papers by this authorAlfredo Fernández-Quintela
Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country (UPV/EHU) and Lucio Lascaray Centre, Vitoria, Spain
CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III (ISCIII), Spain
Search for more papers by this authorMaria P. Portillo
Nutrition and Obesity Group, Department of Nutrition and Food Science, University of the Basque Country (UPV/EHU) and Lucio Lascaray Centre, Vitoria, Spain
CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health Carlos III (ISCIII), Spain
Search for more papers by this authorCorresponding Author
Christian Carpéné
INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut. National de la Santé et de la Recherche Médicale and Université Paul Sabatier, Toulouse, France
Correspondence to: Christian Carpéné, Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, INSERM U1048, Bat L4, CHU Rangueil, 31432 Toulouse, France.
E-mail: [email protected]
Search for more papers by this authorAbstract
The anti-obesity effects of resveratrol shown in rodents are not transposed into an efficient therapy of human obesity. Consequently, the search for molecules mimicking or surpassing resveratrol actions is ongoing. The natural phenolic compound pterostilbene exhibits beneficial health effects and has the capacity to limit fat mass in animal models. In this study, we tested whether pterostilbene modulates triacylglycerol accumulation/breakdown. Prolonged exposure to pterostilbene or resveratrol inhibited adipocyte differentiation in 3T3-F442A preadipocytes. Acute effects on lipolysis, antilipolysis and lipogenesis were determined for pterostilbene in mouse adipocytes, and compared with resveratrol. Pterostilbene was also tested on glycerol release and glucose uptake in subcutaneous human adipocytes. Dose–response analyses did not reveal a clear lipolytic effect in both species. The antilipolytic effect of insulin was improved by pterostilbene at 1–10 μM in mouse fat cells only, while at 1 mM, the phenolic compound was antilipolytic in human fat cells in a manner not additive to insulin. Pterostilbene dose-dependently inhibited glucose incorporation into lipids similarly to resveratrol and caffeine. However, only the former did not inhibit insulin-stimulated glucose uptake. Indeed, pterostilbene abolished the insulin lipogenic effect without inhibiting its antilipolytic action and rapid activation of glucose uptake. Pterostilbene therefore exhibits a unique panel of direct interactions with adipocytes that relies on its reported anti-obesity and antidiabetic properties. Copyright © 2017 John Wiley & Sons, Ltd.
References
- Aguirre L, Milton-Laskibar I, Hijona E, Bujanda L, Rimando AM, Portillo M. 2017. Effects of pterostilbene in brown adipose tissue from obese rats. J Physiol Biochem (in press) . https://doi.org/10.1007/s13105-017-0556-2.
- Arias N, Macarulla MT, Aguirre L, Milton I, Portillo MP. 2016. The combination of resveratrol and quercetin enhances the individual effects of these molecules on triacylglycerol metabolism in white adipose tissue. Eur J Nutr 55(1): 341–348.
- Carpéné C, Gomez-Zorita S, Gupta R, et al. 2014. Combination of low dose of the anti-adipogenic agents resveratrol and phenelzine in drinking water is not sufficient to prevent obesity in very-high-fat diet-fed mice. Eur J Nutr 53(8): 1625–1635.
- Carpéné C, Gomez-Zorita S, Deleruyelle S, Carpéné MA. 2015. Novel strategies for preventing diabetes and obesity complications with natural polyphenols. Curr Med Chem 22(1): 150–164.
- Carpéné C, Galitzky J, Saulnier-Blache JS. 2016a. Short-term and rapid effects of lysophosphatidic acid on human adipose cell lipolytic and glucose uptake activities. AIMS Molec Sci 3: 222–237.
- Carpéné C, Hasnaoui M, Balogh B, et al. 2016b. Dietary phenolic compounds interfere with the fate of hydrogen peroxide in human adipose tissue but do not directly inhibit primary amine oxidase activity. Oxid Med Cell Longev 2016: 2427618. https://doi.org/10.1155/2016/2427618. Epub 2016 Jan 5.
- Chang CC, Lin KY, Peng KY, Day YJ, Hung LM. 2016. Resveratrol exerts anti-obesity effects in high-fat diet obese mice and displays differential dosage effects on cytotoxicity, differentiation, and lipolysis in 3T3-L1 cells. Endocr J 63(2): 169–178.
- Colitti M, Stefanon B. 2016. Different anti-adipogenic effects of bio-compounds on primary visceral pre-adipocytes and adipocytes. EXCLI J 15: 362–377.
- Dong GZ, Lee YI, Jeong JH, et al. 2015. Stilbenoids from Rheum undulatum protect hepatocytes against oxidative stress through AMPK activation. Phytother Res 29(10): 1605–1609.
- Etxeberria U, Hijona E, Aguirre L, et al. 2017. Pterostilbene-induced changes in gut microbiota composition in relation to obesity. Mol Nutr Food Res 61(1).
- Fernandez-Quintela A, Carpéné C, Fernandez M, et al. 2016. Anti-obesity effects of resveratrol: comparison between animal models and humans. J Physiol Biochem (in press) . https://doi.org/10.1007/s13105-016-0544-y.
10.1007/s13105-016-0544-y Google Scholar
- Fève B, Pairault J. 1987. Dexamethasone-dependent expression of beta 1-24 corticotropin stimulated adenylate cyclase during adipose conversion of 3T3-F442A cells. FEBS Lett 219(1): 56–64.
- Fischer-Posovszky P, Kukulus V, Tews D, et al. 2010. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr 92(1): 5–15.
- Gomez-Zorita S, Fernandez-Quintela A, Lasa A, Hijona E, Bujanda L, Portillo MP. 2013a. Effects of resveratrol on obesity-related inflammation markers in adipose tissue of genetically obese rats. Nutrition 29(11–12): 1374–1380.
- Gomez-Zorita S, Treguer K, Mercader J, Carpéné C. 2013b. Resveratrol directly affects in vitro lipolysis and glucose transport in human fat cells. J Physiol Biochem 69(3): 585–593.
- Gomez-Zorita S, Fernandez-Quintela A, Lasa A, Aguirre L, Rimando AM, Portillo MP. 2014. Pterostilbene, a dimethyl ether derivative of resveratrol, reduces fat accumulation in rats fed an obesogenic diet. J Agric Food Chem 62(33): 8371–8378.
- Gomez-Zorita S, Fernandez-Quintela A, Aguirre L, Macarulla MT, Rimando AM, Portillo MP. 2015. Pterostilbene improves glycaemic control in rats fed an obesogenic diet: involvement of skeletal muscle and liver. Food Funct 6(6): 1968–1976.
- Gracia A, Elcoroaristizabal X, Fernandez-Quintela A, et al. 2014. Fatty acid synthase methylation levels in adipose tissue: effects of an obesogenic diet and phenol compounds. Genes Nutr 9(4): 411.
- Grès S, Canteiro S, Mercader J, Carpéné C. 2013. Oxidation of high doses of serotonin favors lipid accumulation in mouse and human fat cells. Mol Nutr Food Res 57(6): 1089–1099.
- Grootaert C, Kamiloglu S, Capanoglu E, Van Camp J. 2015. Cell systems to investigate the impact of polyphenols on cardiovascular health. Forum Nutr 7(11): 9229–9255.
- Hsu CL, Lin YJ, Ho CT, Yen GC. 2012. Inhibitory effects of garcinol and pterostilbene on cell proliferation and adipogenesis in 3T3-L1 cells. Food Funct 3(1): 49–57.
- Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. 2011. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 68(3): 593–601.
- Kim S, Jin Y, Choi Y, Park T. 2011. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 81(11): 1343–1351.
- Kosuru R, Rai U, Prakash S, Singh A, Singh S. 2016. Promising therapeutic potential of pterostilbene and its mechanistic insight based on preclinical evidence. Eur J Pharmacol 789: 229–243.
- Krawczyk SA, Haller JF, Ferrante T, Zoeller RA, Corkey BE. 2012. Reactive oxygen species facilitate translocation of hormone sensitive lipase to the lipid droplet during lipolysis in human differentiated adipocytes. PLoS One 7(4): e34904.
- Lasa A, Schweiger M, Kotzbeck P, et al. 2012. Resveratrol regulates lipolysis via adipose triglyceride lipase. J Nutr Biochem 23(4): 379–384.
- Lee H, Kim JW. 2013. High-dose resveratrol inhibits insulin signaling pathway in 3T3-L1 adipocytes. J Lifestyle Med 3(1): 41–47.
- Les F, Deleruyelle S, Cassagnes LE, et al. 2016. Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties. Chem Biol Interact 258: 115–125.
- Li S, Bouzar C, Cottet-Rousselle C, et al. 2016. Resveratrol inhibits lipogenesis of 3T3-L1 and SGBS cells by inhibition of insulin signaling and mitochondrial mass increase. Biochim Biophys Acta 1857(6): 643–652.
- Lin VC, Tsai YC, Lin JN, et al. 2012. Activation of AMPK by pterostilbene suppresses lipogenesis and cell-cycle progression in p53 positive and negative human prostate cancer cells. J Agric Food Chem 60(25): 6399–6407.
- Moody AJ, Stan MA, Stan M, Gliemann J. 1974. A simple free fat cell bioassay for insulin. Horm Metab Res 6(1): 12–16.
- Nakabayashi H, Hashimoto T, Ashida H, Nishiumi S, Kanazawa K. 2008. Inhibitory effects of caffeine and its metabolites on intracellular lipid accumulation in murine 3T3-L1 adipocytes. Biofactors 34(4): 293–302.
- Otake Y, Nolan AL, Walle UK, Walle T. 2000. Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol 73(5): 265–270.
- Park HJ, Yang JY, Ambati S, et al. 2008. Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J Med Food 11(4): 773–783.
- Riche DM, McEwen CL, Riche KD, et al. 2013. Analysis of safety from a human clinical trial with pterostilbene. J Toxicol 2013: 463595.
- Riche DM, Riche KD, Blackshear CT, et al. 2014. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med 2014: 459165.
- Rimando AM, Nagmani R, Feller DR, Yokoyama W. 2005. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agric Food Chem 53(9): 3403–3407.
- Roupe KA, Remsberg CM, Yanez JA, Davies NM. 2006. Pharmacometrics of stilbenes: seguing towards the clinic. Curr Clin Pharmacol 1(1): 81–101.
- Szkudelska K, Nogowski L, Szkudelski T. 2009a. The inhibitory effect of resveratrol on leptin secretion from rat adipocytes. Eur J Clin Invest 39(10): 899–905.
- Szkudelska K, Nogowski L, Szkudelski T. 2009b. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol 113(1–2): 17–24.
- Vang O, Ahmad N, Baile CA, et al. 2011. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6(6): e19881.
- Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32(12): 1377–1382.
- Wang S, Moustaid-Moussa N, Chen L, et al. 2014. Novel insights of dietary polyphenols and obesity. J Nutr Biochem 25(1): 1–18.
- Warnke I, Jocken JW, Schoop R, Toepfer C, Goralczyk R, Schwager J. 2016. Combinations of bio-active dietary constituents affect human white adipocyte function in-vitro. Nutr Metab (Lond) 13: 84.
Citing Literature
